Literature DB >> 31919349

Opioid use disorder.

John Strang1,2, Nora D Volkow3, Louisa Degenhardt4, Matthew Hickman5, Kimberly Johnson6, George F Koob7, Brandon D L Marshall8, Mark Tyndall9, Sharon L Walsh10.   

Abstract

Opioid use disorder (OUD) is a chronic relapsing disorder that, whilst initially driven by activation of brain reward neurocircuits, increasingly engages anti-reward neurocircuits that drive adverse emotional states and relapse. However, successful recovery is possible with appropriate treatment, although with a persisting propensity to relapse. The individual and public health burdens of OUD are immense; 26.8 million people were estimated to be living with OUD globally in 2016, with >100,000 opioid overdose deaths annually, including >47,000 in the USA in 2017. Well-conducted trials have demonstrated that long-term opioid agonist therapy with methadone and buprenorphine have great efficacy for OUD treatment and can save lives. New forms of the opioid receptor antagonist naltrexone are also being studied. Some frequently used approaches have less scientifically robust evidence but are nevertheless considered important, including community preventive strategies, harm reduction interventions to reduce adverse sequelae from ongoing use and mutual aid groups. Other commonly used approaches, such as detoxification alone, lack scientific evidence. Delivery of effective prevention and treatment responses is often complicated by coexisting comorbidities and inadequate support, as well as by conflicting public and political opinions. Science has a crucial role to play in informing public attitudes and developing fuller evidence to understand OUD and its associated harms, as well as in obtaining the evidence today that will improve the prevention and treatment interventions of tomorrow.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31919349     DOI: 10.1038/s41572-019-0137-5

Source DB:  PubMed          Journal:  Nat Rev Dis Primers        ISSN: 2056-676X            Impact factor:   52.329


  312 in total

1.  Drug policy and the public good: evidence for effective interventions.

Authors:  John Strang; Thomas Babor; Jonathan Caulkins; Benedikt Fischer; David Foxcroft; Keith Humphreys
Journal:  Lancet       Date:  2012-01-07       Impact factor: 79.321

2.  Trends in opioid analgesic abuse and mortality in the United States.

Authors:  Richard C Dart; Hilary L Surratt; Theodore J Cicero; Mark W Parrino; S Geoff Severtson; Becki Bucher-Bartelson; Jody L Green
Journal:  N Engl J Med       Date:  2015-01-15       Impact factor: 91.245

Review 3.  Management of opioid use disorder in the USA: present status and future directions.

Authors:  Carlos Blanco; Nora D Volkow
Journal:  Lancet       Date:  2019-03-14       Impact factor: 79.321

Review 4.  What data are available on the extent of illicit drug use and dependence globally? Results of four systematic reviews.

Authors:  Louisa Degenhardt; Chiara Bucello; Bianca Calabria; Paul Nelson; Anna Roberts; Wayne Hall; Michael Lynskey; Lucas Wiessing; Maria Elena Medina Mora; Nico Clark; Johanna Thomas; Christina Briegleb; Jennifer McLaren
Journal:  Drug Alcohol Depend       Date:  2011-03-05       Impact factor: 4.492

5.  Efficacy and cost-effectiveness of an adjunctive personalised psychosocial intervention in treatment-resistant maintenance opioid agonist therapy: a pragmatic, open-label, randomised controlled trial.

Authors:  John Marsden; Garry Stillwell; Kirsty James; James Shearer; Sarah Byford; Jennifer Hellier; Michael Kelleher; Joanna Kelly; Caroline Murphy; Luke Mitcheson
Journal:  Lancet Psychiatry       Date:  2019-04-02       Impact factor: 27.083

6.  Transition to injection amongst opioid users in Iran: implications for harm reduction.

Authors:  Mohsen Malekinejad; Mohsen Vazirian
Journal:  Int J Drug Policy       Date:  2011-10-13

7.  HIV risk behavior among injection drug users in Tehran, Iran.

Authors:  Nooshin Razani; Minoo Mohraz; Parastoo Kheirandish; Mohsen Malekinejad; Hossein Malekafzali; Azarakhsh Mokri; Willi McFarland; George Rutherford
Journal:  Addiction       Date:  2007-07-23       Impact factor: 6.526

8.  Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50,000 adults in Iran.

Authors:  Hooman Khademi; Reza Malekzadeh; Akram Pourshams; Elham Jafari; Rasool Salahi; Shahryar Semnani; Behrooz Abaie; Farhad Islami; Siavosh Nasseri-Moghaddam; Arash Etemadi; Graham Byrnes; Christian C Abnet; Sanford M Dawsey; Nicholas E Day; Paul D Pharoah; Paolo Boffetta; Paul Brennan; Farin Kamangar
Journal:  BMJ       Date:  2012-04-17

9.  Estimated Prevalence of Opioid Use Disorder in Massachusetts, 2011-2015: A Capture-Recapture Analysis.

Authors:  Joshua A Barocas; Laura F White; Jianing Wang; Alexander Y Walley; Marc R LaRochelle; Dana Bernson; Thomas Land; Jake R Morgan; Jeffrey H Samet; Benjamin P Linas
Journal:  Am J Public Health       Date:  2018-10-25       Impact factor: 11.561

10.  Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health.

Authors:  Beth Han; Wilson M Compton; Carlos Blanco; Elizabeth Crane; Jinhee Lee; Christopher M Jones
Journal:  Ann Intern Med       Date:  2017-08-01       Impact factor: 25.391

View more
  67 in total

1.  Adenosine Monophosphate-activated Protein Kinase (AMPK) in serotonin neurons mediates select behaviors during protracted withdrawal from morphine in mice.

Authors:  Darrell Eacret; Julia Noreck; Julie A Blendy
Journal:  Behav Brain Res       Date:  2021-11-27       Impact factor: 3.332

Review 2.  Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.

Authors:  Reda M Chalhoub; Peter W Kalivas
Journal:  Drugs       Date:  2020-10       Impact factor: 9.546

Review 3.  Neuronal mechanisms underlying opioid-induced respiratory depression: our current understanding.

Authors:  Jan-Marino Ramirez; Nicholas J Burgraff; Aguan D Wei; Nathan A Baertsch; Adrienn G Varga; Helen A Baghdoyan; Ralph Lydic; Kendall F Morris; Donald C Bolser; Erica S Levitt
Journal:  J Neurophysiol       Date:  2021-04-07       Impact factor: 2.714

4.  Insights into the Neurobiology of Craving in Opioid Use Disorder.

Authors:  Lindsay M Lueptow; Elizabeth C Shashkova; Margaret G Miller; Christopher J Evans; Catherine M Cahill
Journal:  Curr Anesthesiol Rep       Date:  2020-09-29

5.  Sexually dimorphic neuroimmune response to chronic opioid treatment and withdrawal.

Authors:  Mohit Kumar; Jennifer R Rainville; Kori Williams; Joshua A Lile; Georgia E Hodes; Fair M Vassoler; Jill R Turner
Journal:  Neuropharmacology       Date:  2021-01-22       Impact factor: 5.250

6.  Heroin Seeking and Extinction From Seeking Activate Matrix Metalloproteinases at Synapses on Distinct Subpopulations of Accumbens Cells.

Authors:  Vivian C Chioma; Anna Kruyer; Ana-Clara Bobadilla; Ariana Angelis; Zachary Ellison; Ritchy Hodebourg; Michael D Scofield; Peter W Kalivas
Journal:  Biol Psychiatry       Date:  2020-12-09       Impact factor: 13.382

7.  Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.

Authors:  Nicholas Lintzeris; Adrian J Dunlop; Paul S Haber; Dan I Lubman; Robert Graham; Sarah Hutchinson; Shalini Arunogiri; Victoria Hayes; Peter Hjelmström; Agneta Svedberg; Stefan Peterson; Fredrik Tiberg
Journal:  JAMA Netw Open       Date:  2021-05-03

Review 8.  Review of publications evaluating opioid use in patients with inflammatory rheumatic disease.

Authors:  Christine Anastasiou; Jinoos Yazdany
Journal:  Curr Opin Rheumatol       Date:  2022-03-01       Impact factor: 5.006

9.  Interleukin-1 receptor-associated kinase 4 (IRAK4) in the nucleus accumbens regulates opioid-seeking behavior in male rats.

Authors:  Ruyan Wu; Jianfeng Liu; Jimmy Vu; Yufei Huang; David M Dietz; Jun-Xu Li
Journal:  Brain Behav Immun       Date:  2021-12-24       Impact factor: 7.217

Review 10.  An update on drug-drug interactions between antiretroviral therapies and drugs of abuse in HIV systems.

Authors:  Nuti Desai; Leah Burns; Yuqing Gong; Kaining Zhi; Asit Kumar; Nathan Summers; Santosh Kumar; Theodore J Cory
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-08-31       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.